As a world-leading service provider for microfluidic chip development, Creative Biolabs has successfully established a panel of state-of-the-art microfluidic-based technologies for exploiting a more efficient disease therapeutic regimen. Nowadays, we provide a wide battery of microfluidic solutions for analyzing diverse immune cells, such as DC cells, T cells, and NK cells. We are committed to bringing deep domain expertise to assist our clients in achieving their strategic and operational objectives.
Microfluidic technology has become a popular tool in recent years of studies due to its many applications in pharmaceutical analysis. Microfluidic technology has been classified into several types: lab-on-a-chip technology, droplet microfluidic technology, three-dimensional (3D) cell culture microfluidic technology, as well as tissue/organs-on-chip technology. Pilot studies have demonstrated that microfluidic technology is a high-throughput, high sensitivity, and high accuracy analytical method for predicting the efficacy and toxicity of candidate drugs. Moreover, recent reports have revealed that microfluidic technology can be also used in the diagnosis of various diseases, such as malignant tumors. In particular, microfluidic technology can handle fluids or bioparticles at the micron scale and can be managed by regulating flow rate. Also, microfluidic chips coupled with various kinds of cell capture and labeling techniques are suitable for identifying novel candidate biomarkers potentially involved in disease progression.
Fig.1 Schematic illustration of the integrated microfluidic device. (Jiang, 2017)
The development of early disease diagnosis and drug screening tools has been regarded as the most promising way to reduce cancer mortality and improve clinical outcomes. Among them, the emerging microfluidic technology holds high promises to fulfill rapid and precise analysis cost-effectively, as compared to conventional bench-top testing. Basing on the requirement of microfluidic chip technology in drug discovery, Creative Biolabs offers a full range of microfluidic-based cell capture and labeling technologies solutions for our worldwide clients. Up to now, we have introduced the application of microfluidic chips into many aspects, including but not limited to, nucleic acids analysis, cell analysis, small molecule identification, drug screening, safety, toxicity, and metabolism evaluation.
In our labs, an integrated microfluidic chip for analyzing circulating tumor cells (CTCs) has been generated. Our assay is composed of a deterministic lateral displacement (DLD) element, an automatic purification domain with CD45-labeled immunomagnetic beads, and a cell capture/labeling structure. The data have suggested that our approach can detect positive green fluorescent protein (GFP) with a capture rate of 90%, a purity of 50%, as well as a high throughput of 1 mL/min in the blood sample. Besides, the capture efficiency of our technology has been confirmed by testing 30 patients with metastatic breast cancer. Furthermore, compared with other methods, our technology has displayed obvious advantages in terms of the analysis time, sample volume, and overall cost. Thus, our integrated techniques provide meaningful data to facilitate a thorough understanding of the molecular mechanisms of malignancy in clinical application.
In addition, to meet the demand for a large quantity of cell preparation, we have established a novel microfluidic trap on-chip cell labeling array. This array consists of a streamlined shape of the labeling element, which can minimize cell clogging during capture and release steps. The release efficiency of this array has been evaluated by detecting leukocytes with a panel of flow rates and incubation times. The results have indicated that more than 80% of captured cells can be released after 20 minutes of incubation.
With years of operational experience, Creative Biolabs can provide advanced microfluidic chip development services for checking any cell analysis project. Our scientists specialized in cell and microfluidic technology studies will work with you to establish the most appropriate strategy. Now, we have developed efficient methods to anticipate challenges, overcome difficulties and convert various potential microfluidic chips into commercial products. If you have any special needs in our services or be interested in learning more about our company, please feel free to contact us for more details.
For Research Use Only. Not For Clinical Use.